Suppr超能文献

活体供肺叶移植。

Living-donor lobar lung transplantation.

机构信息

The Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

出版信息

J Heart Lung Transplant. 2024 Jan;43(1):162-168. doi: 10.1016/j.healun.2023.09.006. Epub 2023 Sep 11.

Abstract

Living-donor lobar lung transplantation (LDLLT) is indicated for critically ill patients who would not survive the waiting period in the case of severe brain-dead donor shortage. It is essential to confirm that potential donors are willing to donate without applying psychological pressure from others. In standard LDLLT, the right and left lower lobes donated by 2 healthy donors are implanted into the recipient under cardiopulmonary support. LDLLT can be applied to various lung diseases including restrictive, obstructive, infectious, and vascular lung diseases in both adult and pediatric patients if size matching is acceptable. Functional size matching by measuring donor pulmonary function and anatomical size matching by 3-dimensional computed tomography volumetry are very useful. When 2 donors with ideal size matching are not available, various transplant procedures, such as single lobe, segmental, recipient lobe-sparing, and inverted lobar transplants are valuable options. There seems to be immunological advantages in LDLLT as compared to cadaveric lung transplantation (CLT). Unilateral chronic allograft dysfunction is a unique manifestation after bilateral LDLLT, which may contribute to better prognosis. The growth of adult lung graft implanted into growing pediatric recipients is suggested by radiologic evaluation. Although only 2 lobes are implanted, postoperative pulmonary function is equivalent between LDLLT and CLT. The long-term outcome after LDLLT is similar to or better than that after CLT. The author has performed 164 LDLLTs resulting in 71.6% survival rate at 10 years. All living-donors returned to their previous life styles. Because of possible serious morbidity in donors, LDLLT should be applied only for critically ill patients.

摘要

活体供肺叶移植(LDLLT)适用于因严重脑死亡供体短缺而在等待期间无法存活的重症患者。重要的是要确认潜在供体愿意捐献,而不会受到他人的心理压力。在标准的 LDLLT 中,两名健康供体捐献的右肺下叶和左肺下叶在心肺支持下植入受体。如果可以接受大小匹配,LDLLT 可应用于各种肺部疾病,包括成人和儿科患者的限制性、阻塞性、感染性和血管性肺部疾病。通过测量供体肺功能进行功能大小匹配和通过三维计算机断层扫描体积测量进行解剖大小匹配非常有用。如果没有理想大小匹配的两名供体,则可以选择各种移植程序,如单叶、节段、受者保留肺叶和反向肺叶移植。与尸体肺移植(CLT)相比,LDLLT 似乎具有免疫优势。双侧 LDLLT 后出现单侧慢性移植物功能障碍是一种独特的表现,可能有助于改善预后。影像学评估提示成人肺移植在生长中的儿科受者中的生长。尽管只植入了 2 个肺叶,但 LDLLT 和 CLT 术后的肺功能相当。LDLLT 的长期结果与 CLT 相似或更好。作者已完成 164 例 LDLLT,10 年生存率为 71.6%。所有活体供者都恢复了以前的生活方式。由于供者可能出现严重的发病率,LDLLT 仅应适用于重症患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验